CRMD vs. RARE, ACLX, MTSR, VKTX, AKRO, ALVO, CPRX, CRNX, SRRK, and MOR
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Metsera (MTSR), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.
CorMedix vs.
Ultragenyx Pharmaceutical (NASDAQ:RARE) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
Ultragenyx Pharmaceutical received 804 more outperform votes than CorMedix when rated by MarketBeat users. However, 79.55% of users gave CorMedix an outperform vote while only 77.54% of users gave Ultragenyx Pharmaceutical an outperform vote.
Ultragenyx Pharmaceutical currently has a consensus price target of $90.93, indicating a potential upside of 143.46%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 17.00%. Given Ultragenyx Pharmaceutical's higher possible upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than CorMedix.
In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than CorMedix. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 7 mentions for CorMedix. CorMedix's average media sentiment score of 1.28 beat Ultragenyx Pharmaceutical's score of 1.12 indicating that CorMedix is being referred to more favorably in the news media.
Ultragenyx Pharmaceutical has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 5.2% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
CorMedix has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. CorMedix's return on equity of -79.21% beat Ultragenyx Pharmaceutical's return on equity.
CorMedix has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
Summary
CorMedix beats Ultragenyx Pharmaceutical on 10 of the 19 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
This page (NASDAQ:CRMD) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy CRMD Stock Free CRMD Stock Alerts